flow trial semaglutide kidney 2024 FLOWing with the — NephJC Semaglutide in patients with overweight

Ongoing research is exploring their potential role across a range of conditions, including cardiovascular disease prevention, metabolic liver disease, and addictions medicine

2

Biomarker contextincluding insulin resistance, baseline inflammation, and lipid metabolismfurther refines treatment selection, though genetics alone does not predict exact medication response

Finally, evaluation of small molecule GLP-1R agonists beyond their effectiveness in T2DM and obesity presents a significant area of opportunity

A 2023 systematic review evaluated 17 studies on transdermal weight-loss patches broadly and concluded that no high-quality evidence supports the efficacy of any non-prescription transdermal patch for weight reduction

Blue Cross Blue Shield will review this information as part of their decision-making process